comprehensive -WSS

comprehensive

author：Wikipedia 2025-09-30 06:22:36 - browse：5

Two people in protective equipment work in a lab. — JUAN MABROMATA/AFP via Getty Images

Biosimilars are no longer a new and untested class of medicines. Today, they provide critical treatment options across multiple therapeutic areas. Since the Biologics Price Competition and Innovation Act of 2009 created a regulatory pathway for biosimilar medicine review in the U.S., 37 biosimilars have come to market offering the potential to increase patient choice and cost savings. And according to the 2023 analysis from IQVIA, biosimilars are expected to generate $181 billion in savings for the U.S. health care system over the next five years.

This progress is due, in part, to thoughtfully considered, scientifically robust regulatory standards, which have instilled confidence among health care providers and patients while protecting safety. As a former associate director of therapeutic biologics at the Food and Drug Administration, I had the privilege of helping create and lead implementation of the regulatory framework for biosimilars. The FDA took great care to apply appropriate scientific rigor to the development and approval standards. While I have since moved to Amgen, my goals have remained focused on biosimilar product quality and efficacy, patient safety, and prescriber confidence.

More than a decade later, collective efforts by biosimilar manufacturers and the FDA are paying off.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： With heat waves through August, officials warn of health risks

knowledge

WSS

Hospital price transparency does save money, advocate argues

Senate committee scrutinizes Medicare Advantage brokers

STAT Summit: Michael J. Fox on progress in Parkinson's research

Failure, not just success, should guide future doctors

STAT Summit: Biotech founders on deal

Lawmakers consider Medicare pay reforms for doctors

hotspot

comprehensive

focus

Anesthesiologist group: stop taking Ozempic before surgery

Trump used to be more articulate. What could explain the change?

BioMarin wins approval for gene therapy to treat hemophilia A

Solve the antibiotic resistance crisis with preventive drugs

Guidelines to prevent youth baseball injuries need more muscle

Many breast cancer patients receive more radiation than needed

After affirmative action ruling, medical educators look to 'holistic review'

Paxlovid rebound happens. Why and to whom are still a mystery

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Senate committee scrutinizes Medicare Advantage brokers

Wikipedia

With heat waves through August, officials warn of health risks

Paxlovid rebound happens. Why and to whom are still a mystery

Trump used to be more articulate. What could explain the change?

Pharmacists can make shortage drugs, but at what cost?

Hospital price transparency does save money, advocate argues

Restaurant meals are packed with calories, and we still keep eating them

focus

knowledge

focus

focus